The biochemical role of the PI3K/PKB/mTOR signalling pathway in cell-cycle regulation is now well known. During the onset and development of different forms of cancer it becomes overactive reducing apoptosis and allowing cell proliferation. Therefore, this pathway has become an important target for the treatment of various forms of malignant tumors, including breast cancer and follicular lymphoma. Recently, several more or less selective inhibitors targeting these proteins have been identified. In general, drugs that act on multiple targets within the entire pathway are more efficient than single targeting inhibitors. Multiple inhibitors exhibit high potency and limited drug resistance, resulting in promising anticancer agents. In this context, the present survey focuses on small molecule drugs capable of modulating the PI3K/PKB/mTOR signalling pathway, thus representing drugs or drug candidates to be used in the pharmacological treatment of different forms of cancer.

PI3K/PKB/mTOR 信号通路在细胞周期调节中的生化作用现已众所周知。在不同形式的癌症的发生和发展过程中，它变得过度活跃，减少细胞凋亡并允许细胞增殖。因此，该通路已成为治疗各种形式恶性肿瘤的重要靶点，包括乳腺癌和滤泡性淋巴瘤。最近，已经鉴定出几种或多或少选择性的靶向这些蛋白质的抑制剂。一般来说，作用于整个通路内多个靶点的药物比单一靶向抑制剂更有效。多种抑制剂表现出高效力和有限的耐药性，从而产生有前途的抗癌剂。在这种情况下，